drugset / Trial / NCT05702996

Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies

NCT05702996

Phase 3 Withdrawn University Hospital, Rouen
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this prospective multisite trial is to study the evolution of TMA (thrombotic microangiopathy) induced by gemcitabin and treated by eculizumab.

Timeline

Start
2023-03
Primary completion
2025-09
Completion
2025-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody